TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34969428
Drug: Medication event
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication event reminder monitor system (MERM) with treatment monitor
Study: 34048682
Drug: Camidanlumab tesirine
Normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camidanlumab tesirine (3–150 μg/kg, administered intravenously once every 3 weeks)
Study: 36726737
Drug: Benralizumab 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 100 mg
Study: 36849212
Drug: Placebo (subcutaneous)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous)
Study: 35906582
Drug: routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine oral care with rhIL‐11 mouthwash
Study: 35906582
Drug: routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine oral care
Study: 36473029
Drug: Crocin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (15 mg daily)
Study: 36473029
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg daily)
Study: 34343420
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of hypertonic saline (0.5 ml)
Study: 34343420
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of hypertonic saline (1.0 ml)
Study: 33116482
Drug: 1,100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,100 µg F−/g
Study: 33116482
Drug: 1,100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,100 µg F−/g + nano‐HA
Study: 33116482
Drug: 5,000 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 µg F−/g
Study: 33116482
Drug: 5,000 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 µg F−/g + nano‐HA
Study: 32306477
Drug: Faster aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faster aspart (0.2 U/kg, single-dose subcutaneous)
Study: 32306477
Drug: IAsp (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAsp (0.2 U/kg, single-dose subcutaneous)
Study: 32004201
Drug: Rapid hemorrhage
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid hemorrhage (1.4 ml/min, 30‐min bleeding)
Study: 32004201
Drug: Rapid‐L hemorrhage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid‐L hemorrhage (1.4 ml/min, 30‐min bleeding and observation until 6 h)
Study: 32004201
Drug: Slow hemorrhage
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow hemorrhage (0.1 ml/min, intermittently, 6‐h bleeding)
Study: 32004201
Drug: Control‐L (6‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control‐L (6‐h observation)
Study: 35813851
Drug: 28 mg
Normalized name: aspirin 228 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 mg daily of saffron extract (affron®)
Study: 36410825
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment and colchicine
Study: 36410825
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment only
Study: 36410825
Drug: Control/delayed periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control/delayed periodontal treatment
Study: 32075474
Drug: Butyphthalide injection
Normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyphthalide injection combined with urinary kallikrein
Study: 32075474
Drug: Cinepazide maleate
Normalized name: cinepazide maleate
DrugBank: Cinepazide (DB12123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinepazide maleate injection combined with alprostadil injection
Study: 35581997
Drug: High-dose melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melatonin (21 mg per day for 5 days)
Study: 32138784
Drug: 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg dexmedetomidine (DEX2)
Study: 34129855
Drug: Androgen-deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-deprivation therapy (ADT) + docetaxel (D)
Study: 36497687
Drug: Individualized oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized oral health care training (IndOHCT)
Study: 32701900
Drug: Snus (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snus (8 mg nicotine)
Study: 33949940
Drug: Progestogen-only pill
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen-only pill (75 microg of desogestrel) plus rapid access card to a sexual and reproductive health clinic
Study: 33893754
Drug: evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: evolocumab 140 mg s.c. every 2 weeks on top of ongoing LLT
Study: 32742642
Drug: 2RDA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2RDA (2 times the recommended dietary intake of protein, 1.6 g protein/kg body weight per day)
Study: 32742642
Drug: RDA (recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDA (recommended dietary intake of protein, 0.8 g protein/kg body weight per day)
Study: 36513483
Drug: L-Arg supplementation
Normalized name: L-Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Arg supplementation (3 g oral daily for up to 10 days)
Study: 33206991
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed and cisplatin or carboplatin)
Study: 35701050
Drug: Non-specific supportive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific supportive treatment in addition to standard care (SC)
Study: 33267769
Drug: Oral mosapride
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mosapride (5 mg) before and after surgery with dexamethasone (10 mg)
Study: 33267769
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg) before anesthesia induction
Study: 35147087
Drug: Electro-press needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-press needle (EPN) treatment, 3 sessions per week for 6 weeks (total of 18 sessions)
Study: 35147087
Drug: EPN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPN treatment
Study: 34019214
Drug: CAPOXIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOXIRI plus bevacizumab (irinotecan 200 mg/m2, oxaliplatin 100 mg/m2, capecitabine 1600 mg/m2, bevacizumab 7.5 mg/kg)
Study: 34019214
Drug: CAPOXIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOXIRI plus bevacizumab (irinotecan 200 mg/m2, oxaliplatin 130 mg/m2, capecitabine 1600 mg/m2, bevacizumab 7.5 mg/kg)
Study: 35412495
Drug: Intensive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive hydration (IH) with Ringer's Lactate at a rate of 3 mL/kg/h during and for 8 h following the procedure, plus an additional bolus of 20 mL/kg at the end of the procedure.
Study: 35412495
Drug: Standard hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydration (SH) with Ringer's Lactate at a rate of 1.5 mL/kg/h during and for 8 h following the procedure.
Study: 32860041
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months (ACS)
Study: 32860041
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) combined with a P2Y12 inhibitor and aspirin 100 mg for 1-12 months (ACS)
Study: 32860041
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months (CCS)
Study: 32860041
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) combined with a P2Y12 inhibitor and aspirin 100 mg for 1-12 months (CCS)
Study: 35347756
Drug: Generalized weighted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generalized weighted combination test
Study: 33298127
Drug: Blended online
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended online and human behavioural therapy for tics
Study: 33326316
Drug: DTaP-IPV-HB-PRPT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-HB-PRPT vaccine (administered as a 6, 10, 14 week primary series with a toddler booster at 15-18 months)
Study: 33326316
Drug: DTaP-IPV-HB-PRPT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-HB-PRPT vaccine
Study: 616475925
Drug: Furosemide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (160 mg i.v.)
Study: 616475925
Drug: Hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (100 mg p.o.) plus Furosemide
Study: 32703720
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D oral pill (100,000 IU)
Study: 32703720
Drug: Skin oil
Normalized name: NIVEA SKIN OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin oil application (SOA) plus vitamin D3 suspension with essential oil enhancer
Study: 32703720
Drug: Placebo (pill,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (pill, oral liquid, SOA)
Study: 34773606
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 mg once daily
Study: 34773606
Drug: Finerenone 20
Normalized name: finerenone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 20 mg once daily
Study: 33217785
Drug: eGFR <
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR < 60 mL/min/1.73 m2
Study: 32114889
Drug: Evolocumab (Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (Q2W dose)
Study: 32114889
Drug: Evolocumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (monthly dose)
Study: 33814182
Drug: Phenol treatment
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenol treatment
Study: 33814182
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (excision and primary closure)
Study: 34028808
Drug: 2% simvastatin/2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% simvastatin/2% cholesterol cream applied twice daily
Study: 35583280
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C with chemotherapy
Study: 32720988
Drug: Chikungunya virus-like
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chikungunya virus-like particle vaccine
Study: 34338714
Drug: Fluoxetine hydrochloride,
Normalized name: FLUoxetine Hydrochloride, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride, 20 mg daily for 26 weeks
Study: 33837906
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (500 mL) plus standard drugs
Study: 35202009
Drug: Standard-volume regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-volume regimen (1.0 to 1.5 L of MoviPrep)
Study: 36450379
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg intravenously every 3 weeks)
Study: 34515056
Drug: 20% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% human albumin solution (HAS)
Study: 34515056
Drug: 4% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% human albumin solution (HAS)
Study: 33078978
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles
Study: 33078978
Drug: Doxorubicin 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with granulocyte colony-stimulating factor
Study: 34975146
Drug: Exenatide extended
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide extended release once-weekly (ExQW)
Study: 34190361
Drug: romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: romosozumab 210 mg monthly for 12 months
Study: 34190361
Drug: alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate 70 mg weekly for 12 months
Study: 32379269
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg) daily for 7 days
Study: 34557093
Drug: Interdisciplinary physician-pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary physician-pharmacist medication review
Study: 33667870
Drug: Capsaicin (CAP)
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin (CAP) 150 mg/kg, ad libitum feeding
Study: 33667870
Drug: Capsaicin (CAP)
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin (CAP) 150 mg/kg, pair-fed
Study: 34509801
Drug: safinamide 50
Normalized name: safinamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 50 mg
Study: 34509801
Drug: safinamide 100
Normalized name: safinamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 100 mg
Study: 34509801
Drug: safinamide 50
Normalized name: safinamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 50 mg and 100 mg
Study: 32065514
Drug: PF-05221304 (1-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05221304 (1-240 mg single doses or 2-200 mg daily repeated doses for 14 days)
Study: 32065514
Drug: PF-05221304 (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05221304 (repeated doses)
Study: 32065514
Drug: PF-05221304 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05221304 (doses yielding ≥90% DNL inhibition)
Study: 32065514
Drug: PF-05221304 (steady-state
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05221304 (steady-state pharmacokinetics)
Study: 33623830
Drug: Anti-adhesion gel
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-adhesion gel
Study: 33623830
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel (control group)
Study: 32513069
Drug: Naringin 450
Normalized name: Naringin
DrugBank: Naringin (DB16859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringin 450 mg every 24 hours for 90 days
Study: 33410265
Drug: 5% sofpironium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sofpironium bromide (BBI-4000) gel
Study: 35361724
Drug: Roxadustat (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (oral, three times weekly)
Study: 35361724
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (parenteral, per local clinic practice)
Study: 33608398
Drug: Early continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early continuous renal replacement therapy (CRRT) initiated immediately after randomisation
Study: 33608398
Drug: Delayed continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed continuous renal replacement therapy (CRRT) initiated based on specific criteria (stage 3 KDIGO, severe hyperkalaemia, pulmonary oedema, blood urea nitrogen > 112 mg/dL)
Study: 36126290
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (zero-intensity laser)
Study: 32888230
Drug: Combination nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination nicotine replacement therapy (C‐NRT) (n = 421)
Study: 32888230
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch monotherapy (control) (n = 230)
Study: 35275196
Drug: AZD4017 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4017 (400 mg oral, twice daily for 90 days)
Study: 35644168
Drug: dNS1-RBD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dNS1-RBD vaccine (intranasal spray)
Study: 32002583
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg propranolol orally every 12 hours up to 10 days or until discharge (BB+)
Study: 33966952
Drug: DARTNA (Drum-Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: DARTNA (Drum-Assisted Recovery Therapy for Native Americans)
Study: 32869931
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF, 0.1%) cream with linoleic acid-ceramide (LA-Cer) moisturizer
Study: 32869931
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF, 0.1%) cream
Study: 33559168
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shock wave therapy (Li-ESWT) plus pelvic floor muscle training
Study: 33559168
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle exercise and sham therapy by shock wave
Study: 34830677
Drug: Individual reminiscence
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual reminiscence therapy (RT) sessions, twice weekly for 13 weeks
Study: 34830677
Drug: Regular activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular activities administered as part of their program (Control)
Study: 35996179
Drug: 4 or
Normalized name: Dex4 Orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 or 6 mg NRT chewing gum for 8 weeks
Study: 35996179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interventions A and B
Study: 33355478
Drug: Adjunctive mangosteen
Normalized name: mangostin
DrugBank: Mangostin (DB14371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive mangosteen pericarp (1,000 mg/day)
Study: 32414832
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training programme consisting of motor control exercise and segmental exercises; specific dosage and duration not provided.
Study: 35396879
Drug: Accelerated resolution
Normalized name: Revolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated resolution therapy (ART)
Study: 36325897
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg or 150 mg every 2 weeks as an adjunct to background treatment
Study: 32071052
Drug: Nitazoxanide (NTZ)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (NTZ) 1 g orally twice daily for 14 days
Study: 33909726
Drug: Stress‐free implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress‐free implant bar (SFI‐Bar)
Study: 34529962
Drug: MenACWY (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY (first dose) followed by placebo (second dose) on day 57
Study: 34529962
Drug: Ad26.ZEBOV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen
Study: 32621543
Drug: MHAA4549A 3600
Normalized name: MHAA4549A
DrugBank: Gedivumab (DB15277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAA4549A 3600 mg
Study: 32621543
Drug: MHAA4549A 8400
Normalized name: MHAA4549A
DrugBank: Gedivumab (DB15277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAA4549A 8400 mg
Study: 616766147
Drug: Control treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatments (no AMF or NFB)
Study: 36283845
Drug: Subcutaneous analgesic
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous analgesic system (SAS)
Study: 36177365
Drug: Oxybuprocaine hydrochloride
Normalized name: Oxybuprocaine hydrochloride
DrugBank: Oxybuprocaine (DB00892)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybuprocaine hydrochloride gel as urethral lubricant
Study: 35998039
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (1,000 mg) and pterostilbene (200 mg) supplementation
Study: 35222888
Drug: Psychological care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological care plus Chinese herbal decoction treatment
Study: 32532258
Drug: Danirixin 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin 5, 10, 25, 35 or 50 mg twice daily
Study: 36273218
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50,000 IU weekly for 8 weeks)
Study: 36273218
Drug: Placebo (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1000 mg olive oil weekly for 8 weeks)
Study: 35565880
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of whey protein (WP30)
Study: 35565880
Drug: 70 g
Normalized name: alcohol .70 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g of whey protein (WP70)
Study: 34762377
Drug: danshentong capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: danshentong capsules (1 g, 3 times per day) and 0.1% adapalene gel smear (once every night) for 4 weeks
Study: 32544970
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate in combination with prednisone/prednisolone (abiraterone/P)
Study: 34165201
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg b.d.
Study: 32000070
Drug: QL block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL block (0.375% ropivacaine 20 ml bilaterally)
Study: 32000070
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block (0.375% ropivacaine 20 ml bilaterally)
Study: 35549730
Drug: Non-SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-SGLT2 inhibitors